See more : Fuji Kosan Company, Ltd. (5009.T) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroPace, Inc. (NPCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroPace, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Sunwin Stevia International, Inc. (SUWN) Income Statement Analysis – Financial Results
- HYUGA PRIMARY CARE Co.,Ltd. (7133.T) Income Statement Analysis – Financial Results
- HanseYachts AG (H9Y.DE) Income Statement Analysis – Financial Results
- New Pacific Metals Corp. (NUAG.TO) Income Statement Analysis – Financial Results
- Gravitas Education Holdings, Inc. (GEHI) Income Statement Analysis – Financial Results
NeuroPace, Inc. (NPCE)
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 65.42M | 45.52M | 45.18M | 41.14M | 36.97M |
| Cost of Revenue | 17.30M | 13.03M | 11.75M | 10.87M | 10.51M |
| Gross Profit | 48.12M | 32.49M | 33.44M | 30.27M | 26.46M |
| Gross Profit Ratio | 73.56% | 71.38% | 74.00% | 73.59% | 71.58% |
| Research & Development | 20.78M | 21.95M | 18.21M | 15.70M | 18.29M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.52M | 51.34M | 38.96M | 27.63M | 30.20M |
| Other Expenses | 0.00 | -337.00K | -5.38M | 218.00K | 1.28M |
| Operating Expenses | 75.30M | 73.29M | 57.17M | 43.32M | 48.50M |
| Cost & Expenses | 92.60M | 86.31M | 68.92M | 54.19M | 59.00M |
| Interest Income | 3.05M | 1.58M | 448.00K | 41.00K | 261.00K |
| Interest Expense | 8.52M | 7.53M | 7.41M | 11.49M | 9.49M |
| Depreciation & Amortization | 1.61M | 2.99M | 296.00K | 312.00K | 421.00K |
| EBITDA | -22.83M | -36.57M | -28.37M | -12.48M | -20.07M |
| EBITDA Ratio | -34.90% | -86.89% | -62.80% | -30.34% | -54.28% |
| Operating Income | -27.17M | -40.79M | -23.74M | -13.05M | -22.03M |
| Operating Income Ratio | -41.54% | -89.62% | -52.54% | -31.72% | -59.59% |
| Total Other Income/Expenses | -5.78M | -6.29M | -12.34M | -11.23M | -7.94M |
| Income Before Tax | -32.96M | -47.08M | -36.08M | -24.28M | -29.97M |
| Income Before Tax Ratio | -50.38% | -103.43% | -79.85% | -59.02% | -81.07% |
| Income Tax Expense | 0.00 | 6.29M | 2.03M | 11.70M | 10.77M |
| Net Income | -32.96M | -53.37M | -38.11M | -35.98M | -40.74M |
| Net Income Ratio | -50.38% | -117.25% | -84.34% | -87.47% | -110.19% |
| EPS | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
| EPS Diluted | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
| Weighted Avg Shares Out | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
| Weighted Avg Shares Out (Dil) | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 31.5% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
RNS System to be featured in over 70 scientific presentations and posters Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the treatment experience for physicians and patients NeuroPace's Booth...
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy
What Makes NeuroPace (NPCE) a New Buy Stock
NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade
The mean of analysts' price targets for NeuroPace (NPCE) points to a 54.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Frank Takkinen –...
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago.
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy
The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug - resistant focal epilepsy
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?
NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024...
Source: https://incomestatements.info
Category: Stock Reports